Amalgamated Bank Acquires 222 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Amalgamated Bank boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 46,695 shares of the biotechnology company’s stock after acquiring an additional 222 shares during the period. Amalgamated Bank’s holdings in Sarepta Therapeutics were worth $5,678,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. boosted its position in shares of Sarepta Therapeutics by 896.5% in the 3rd quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 511 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Sarepta Therapeutics by 59,222.7% in the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock valued at $9,483,000 after buying an additional 75,805 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sarepta Therapeutics by 112.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock worth $747,000 after buying an additional 3,180 shares during the last quarter. State of Alaska Department of Revenue grew its position in shares of Sarepta Therapeutics by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock worth $1,378,000 after buying an additional 750 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 155 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 3.6 %

NASDAQ:SRPT opened at $103.06 on Friday. The firm has a market capitalization of $9.84 billion, a price-to-earnings ratio of 82.45 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $101.00 and a twelve month high of $173.25. The stock’s 50 day moving average price is $116.14 and its two-hundred day moving average price is $122.76.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

SRPT has been the topic of several recent analyst reports. Royal Bank of Canada reduced their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday. Guggenheim lifted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. Finally, Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.82.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.